SiTime Corporation vs Smith & Nephew plc — how do they compare? SiTime Corporation trades at $598 (market cap $16.63B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: SiTime Corporation is the larger of the two by market cap, and Smith & Nephew plc pays a 2.57% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| SITM | SNN | |
|---|---|---|
Market Cap | $16.63B | $12.64B |
Sector | Technology | Health |
52-Week High | $901.60 | $38.70 |
52-Week Low | $190.16 | $28.73 |
Enterprise Value | $15.84B | $15.41B |
Dividend Yield | — | 2.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Trailing returns across standard periods
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →